| aortic stenosis | All results are NS for efficacy inferior to standard therapy in terms of Stroke or TIA in PARTNER, 2010 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PARTNER, 2010 | vs standard therapy | death from any cause 0.62 [0.47; 0.81] Death from any cause or major stroke 0.66 [0.51; 0.85] | Stroke or TIA 2.38 [1.07; 5.28] | major stroke 2.00 [0.83; 4.84] | | PARTNER cohort A, 2011 | vs standard therapy | | | |
| Trial | Treatments | Patients | Method |
|---|
| PARTNER, 2010 | transcatheter aortic-valve
implantation (TAVI)with Edwards SAPIEN Transcatheter Heart Valve
(n=179) vs. standard therapy (n=179) | patients with severe aortic stenosis considered
not to be suitable candidates for surgery | open Parallel groups Sample size: 179/179 Primary endpoint: death from any cause FU duration: 1.6 y (at least1 year) | | PARTNER cohort A, 2011 | percutaneous valve implantation (Sapien device) (n=699) vs. surgical valve replacement
(n=0) | high risk, symptomatic patients with severe aortic stenosis | Parallel groups Sample size: 699/0 Primary endpoint: FU duration: |
|
